Jun 1, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
May 27, 2020 • 8:05 am EDT Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
May 22, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
May 11, 2020 • 7:05 am EDT Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
Apr 29, 2020 • 8:05 am EDT Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Results in Arthritis & Rheumatology
Mar 12, 2020 • 7:05 am EDT Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
Mar 10, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
Mar 5, 2020 • 8:05 am EST Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020